Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: "uveal melanoma" Condition: Melanoma Clear all
Completed Phase 1 Interventional

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

NCT04082962
View directory record Official record
Conditions
Exudative Retinal Detachment and Uveal Melanoma
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Ivana K. Kim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 14, 2026, 5:45 AM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 14, 2026, 5:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

NCT06413680
View directory record Official record
Conditions
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions
REGN10597, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

NCT02029690
View directory record Official record
Conditions
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

NCT04552223
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Jose Lutzky, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Active, not recruiting No phase listed Observational

Eye Plaque Brachytherapy for Ocular Melanoma

NCT06432660
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Data collection
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

NCT00288041
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Interventions
carboplatin, paclitaxel, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 14, 2026, 5:45 AM EDT
Completed No phase listed Observational

Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

NCT00351728
View directory record Official record
Conditions
Ocular Melanoma, Choroidal Melanoma, Uveal Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 14, 2026, 5:45 AM EDT
Active, not recruiting Phase 1 Interventional

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

NCT05496686
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201, 38 microCi of 225Ac-MTI-201, 76 microCi of 225Ac-MTI-201, 152 microCi of 225Ac-MTI-201, 254 microCi of 225Ac-MTI-201, 424 microCi of 225Ac-MTI-201, 564 microCi of 225Ac-MTI-201, 750 microCi of 225Ac-MTI-201, 998 microCi of 225Ac-MTI-201, 1327 microCi of 225Ac-MTI-201
Drug
Lead sponsor
Modulation Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Not listed Phase 1 Interventional

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

NCT00986661
View directory record Official record
Conditions
Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
Interventions
PV-10 (10% rose bengal disodium)
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
Light-activated AU-011, Laser Activation
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced Melanoma

NCT00705640
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy
Biological · Procedure
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

NCT03408587
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
CVA21, Ipilimumab
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami Beach, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 14, 2026, 5:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

NCT03611868
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions
Phase 1b: APG-115+pembrolizumab
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
12 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

NCT05308901
View directory record Official record
Conditions
Melanoma, Uveal
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00471471
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions
Peptide vaccine, GM-CSF, PF3512676
Biological
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347
View directory record Official record
Conditions
Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

NCT00085306
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
recombinant interferon beta
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Taxoprexin® Treatment for Advanced Eye Melanoma

NCT00244816
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Taxoprexin
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
13 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 5:45 AM EDT
Recruiting Phase 1 Interventional

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

NCT04282044
View directory record Official record
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions
CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
Biological · Combination Product
Lead sponsor
BioEclipse Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

NCT01430416
View directory record Official record
Conditions
Uveal Melanoma
Interventions
AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

NCT00027742
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pegylated interferon alfa, temozolomide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 14, 2026, 5:45 AM EDT